phase readout
saveNCT05513001: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
ACTIVE_NOT_RECRUITINGupdated 19d ago
community read0 votes
Sponsor: Novartis Pharmaceuticals. Phase: PHASE3. Conditions: Chronic Spontaneous Urticaria
view source ↗
comments(0)
5-min edit window · permanent after that